Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Download PDF Copy

Apr 29 2015

NewsGuard 100/100 Score

Oncolytics Biotech^® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency ("EMA") has granted Orphan Drug Designation for its lead product candidate, REOLYSIN^®, for the treatment of pancreatic cancer.

"Our submission to the EMA included survival data from our single arm gemcitabine/REOLYSIN^® (REO 017) clinical study in pancreatic cancer patients, which factored into their decision to grant us the designation," said Dr. Brad Thompson, President and CEO of Oncolytics.

Source:

Oncolytics Biotech Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Biotechnology, Cancer, Cancer Therapy, Cancer Treatment, Gemcitabine, Pancreatic Cancer, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Rare genetic mutations in healthy women may be key to breast cancer origins

Rare genetic mutations in healthy women may be key to breast cancer origins

AI models redefine TIL scoring in breast cancer but face challenges in real-world validation

AI models redefine TIL scoring in breast cancer but face challenges in real-world validation

How different types of bread impact cancer risk

How different types of bread impact cancer risk

Study reveals how cancer cells evade chemotherapy in low-glucose environments

Study reveals how cancer cells evade chemotherapy in low-glucose environments

Researchers uncover key genes linked to DCIS progression

Researchers uncover key genes linked to DCIS progression

Revolutionary strategy offers hope for type 1 diabetes treatment

Revolutionary strategy offers hope for type 1 diabetes treatment

History of endometriosis and fibroids linked to higher long-term risk of early death

History of endometriosis and fibroids linked to higher long-term risk of early death

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Nanoparticle coating enhances cancer drug delivery and reduces side effects